ClinicalTrials.gg
CompletedNCT06637423TroFuse-027Updated Nov 5, 2026

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

A Phase 1/2 interventional study of Sacituzumab tirumotecan and Rescue medication in Non-Muscle Invasive Bladder Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 13 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

Updated Nov 5, 2026Now CompletedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States — 39 open to participants now, 60 under way, 15 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United States.

Enrollment
59th of 93
35 · median 55
Started
2024
with 9 others
Phase 1/2
21 of 114
6 open now
Registered
91st of 114
by date

Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, this one is the 59th largest by enrollment of the 93 interventional ones that give a count, is one of 10 that started in 2024, is one of 21 in phase 1/2, and was the 91st registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

39 of the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.

03

Conditions studied

  • Non-Muscle Invasive Bladder Cancer

Keywords

  • Non-Muscle Invasive Bladder Cancer
  • Low Grade
  • Intermediate Risk
  • Recurrent Low-Grade
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Has recurrent low-grade (Ta) Non-Muscle Invasive Bladder Cancer (NMIBC) in the bladder
  • Must have visible tumor by cystoscopy within 12 weeks prior to first dose
  • Has intermediate-risk NMIBC defined as 1 or more of the following risk factors:

    • Multiple tumors
    • >1 occurrence of low-grade NMIBC within 1 year of the current diagnosis at Screening
    • Early recurrence (\<1 year) of the initial diagnosis of low-grade disease
    • Solitary tumor >3 cm
    • Failure of prior intravesical treatment
  • An (ECOG) performance status of 0 to 2 assessed within 14 days prior to first dose

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Newly diagnosed low-grade non-muscle invasive bladder cancer (Ta NMIBC) in the bladder
  • Past or current history of high-grade (Ta or T1 or CIS) NMIBC, muscle invasive bladder cancer (MIBC) or urothelial carcinoma (UC)
  • Has a condition that would prohibit normal voiding (or hold bladder voiding for 1 to 2 hours)
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease, and/or blepharitis, or severe corneal disease that prevents and/or delays corneal healing
  • Has active inflammatory bowel disease requiring medication or previous history of inflammatory bowel disease (eg, Chron's disease, ulcerative colitis, or chronic diarrhea)
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
  • Known additional that is progressing or has required active treatment within the past 3 years
  • History of (noninfectious) pneumonitis/interstitial lung disease that required or has current pneumonitis/interstitial lung disease.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Sacituzumab tirumotecan

    Participants receive intravesical Sacituzumab Tirumotecan for 6 weeks

    Drug: Sacituzumab tirumotecan · Drug: Rescue medication · Drug: Supportive care measures

Interventions

  • Intravesical administration

    Also known as: SKB264, sac-TMT, MK-2870

  • DrugRescue medication

    Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.

  • DrugSupportive care measures

    Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicity (DLT)

    DLT will be defined as any drug-related adverse event (AE) observed during the DLT evaluation period (7 weeks). All toxicities will be graded using National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) version 5.0.

    Time frame: Up to approximately 7 weeks

  2. Number of Participants Experiencing an Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant administered a study treatment which did not necessarily have to have a causal relationship with this treatment. An AE could be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of study treatment, is also an AE. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 10 weeks

  3. Number of Participants Discontinuing Study Treatment due to an Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant administered a study treatment which did not necessarily have to have a causal relationship with this treatment. An AE could be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of study treatment, is also an AE. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 6 weeks

Secondary outcomes

  1. Area Under the Serum Concentration-Time Curve (AUC) of sacituzumab tirumotecan (sac-TMT) Antibody-Drug Conjugate (ADC)

    Blood samples will be collected to determine the AUC of sac-TIMT ADC

    Time frame: Up to approximately 6 weeks

  2. Maximum Serum Concentration (Cmax) of sac-TMT ADC

    Blood samples will be collected to determine the Cmax of sac-TMT ADC

    Time frame: Up to approximately 6 weeks

  3. Minimum Serum Concentration (Cmin) of sac-TMT ADC

    Blood samples will be collected to determine the Cmin of sac-TMT ADC

    Time frame: Up to approximately 6 weeks

  4. Serum Apparent terminal half-life (t½) of sac-TMT ADC

    Blood samples will be collected to determine the t1/2 of sac-TMT ADC

    Time frame: Up to approximately 6 weeks

  5. Serum AUC of sac-TMT Total Antibody (TAb)

    Blood samples will be collected to determine the AUC of sac-TMT Tab

    Time frame: Up to approximately 6 weeks

  6. Serum Cmax of sac-TMT Tab

    Blood samples will be collected to determine the Cmax of sac-TMT Tab

    Time frame: Up to approximately 6 weeks

  7. Serum Cmin of sac-TMT Tab

    Blood samples will be collected to determine the Cmin of sac-TMT Tab

    Time frame: Up to approximately 6 weeks

  8. Serum t½ of sac-TMT Tab

    Blood samples will be collected to determine the t1/2 of sac-TMT Tab

    Time frame: Up to approximately 6 weeks

  9. Plasma AUC of sac-TMT payload

    Blood samples will be collected to determine the AUC of sac-TMT payload

    Time frame: Up to approximately 6 weeks

  10. Plasma Cmax of sac-TMT payload

    Blood samples will be collected to determine the Cmax of sac-TMT payload

    Time frame: Up to approximately 6 weeks

  11. Plasma Cmin of sac-TMT payload

    Blood samples will be collected to determine the Cmin of sac-TMT payload

    Time frame: Up to approximately 6 weeks

  12. Plasma t½ of sac-TMT payload

    Blood samples will be collected to determine the t1/2 of sac-TMT payload

    Time frame: Up to approximately 6 weeks

  13. Complete Response Rate (CRR)

    CRR is defined as the percentage of participants who will be absent of residual tumor in the bladder assessed locally by cystoscopy evaluation and negative urine cytology and/or biopsy and imaging if applicable.

    Time frame: Up to approximately 6 months

  14. Duration of Complete Response (DCR)

    Duration of CR for participants who demonstrate CR is defined as the time from the first documented evidence of CR (absence of residual tumor in the bladder assessed locally by cystoscopy evaluation and negative urine cytology and/or biopsy and imaging if applicable) until the occurrence of histologically confirmed nonmuscle invasive urothelial carcinoma (UC) by local pathology review or locally advanced or metastatic UC, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 24 months

07

Study locations

13 sites
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2024 to primary completion in Sep 2026, 21 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Mar 2029 → Sep 2026 and completion Mar 2029 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
Dec 20, 2024
Primary completionActual
Sep 30, 2026was Mar 2029
CompletionActual
Sep 30, 2026was Mar 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 5, 2026
Sites
1 site added, 1 site removed. 11 sites changed recruiting status (11 now active, not recruiting)
Show 11 sites
  • Hôpital Claude Huriez ( Site 0012) · Lille, FranceRecruiting→Active, not recruiting
  • HENRI MONDOR HOSPITAL ( Site 0011) · Créteil, FranceRecruiting→Active, not recruiting
  • Gustave Roussy ( Site 0013) · Villejuif, FranceRecruiting→Active, not recruiting
  • Michael G Oefelein Clinical Trials ( Site 0053) · Bakersfield, United StatesRecruiting→Active, not recruiting
  • Moffitt Cancer Center ( Site 0057) · Tampa, United StatesRecruiting→Active, not recruiting
  • Northwestern University ( Site 0051) · Chicago, United StatesRecruiting→Active, not recruiting
  • Johns Hopkins University ( Site 0055) · Baltimore, United StatesRecruiting→Active, not recruiting
  • Princess Margaret Cancer Centre ( Site 0003) · Toronto, CanadaRecruiting→Active, not recruiting
  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0002) · Sherbrooke, CanadaRecruiting→Active, not recruiting
  • Hospital Universitario Virgen de la Victoria ( Site 0043) · Málaga, SpainRecruiting→Active, not recruiting
  • Hospital Universitario 12 de Octubre ( Site 0042) · Madrid, SpainRecruiting→Active, not recruiting
Show site
  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0002) · Sherbrooke, Canada
Show 1 removed
  • CIUSSS de l'Estrie-CHUS ( Site 0002) · Sherbrooke, Canada
across 2 updates, Oct 6, 2026 – Oct 15, 2026
Primary completion
Mar 14, 2029→Sep 30, 2026 (actual)
Nov 5, 2026
Study completion
Mar 14, 2029→Sep 30, 2026 (actual)
Nov 5, 2026
Enrollment
32 (estimated)→35 (actual)
Nov 5, 2026
Site contacts
Changed at 11 sites. See the sites
Show 11 sites
  • Moffitt Cancer Center ( Site 0057) · Tampa, United StatesContact removed •••4488
  • Hôpital Claude Huriez ( Site 0012) · Lille, FranceContact removed •••4398
  • HENRI MONDOR HOSPITAL ( Site 0011) · Créteil, FranceContact removed •••1349
  • Gustave Roussy ( Site 0013) · Villejuif, FranceContact removed •••4211
  • Michael G Oefelein Clinical Trials ( Site 0053) · Bakersfield, United StatesContact removed •••1063
  • Northwestern University ( Site 0051) · Chicago, United StatesContact removed •••1102
  • Johns Hopkins University ( Site 0055) · Baltimore, United StatesContact removed •••0009
  • Princess Margaret Cancer Centre ( Site 0003) · Toronto, CanadaContact removed •••2246
  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0002) · Sherbrooke, CanadaContact removed •••3446
  • Hospital Universitario Virgen de la Victoria ( Site 0043) · Málaga, SpainContact removed •••2095
  • Hospital Universitario 12 de Octubre ( Site 0042) · Madrid, SpainContact removed •••8121
across 2 updates, Oct 6, 2026 – Oct 15, 2026
Show all 3 updates
  1. Nov 5, 2026
    Recruiting→Completed
    Primary completion Mar 14, 2029→Sep 30, 2026 (now actual)
    Study completion Mar 14, 2029→Sep 30, 2026 (now actual)
    Enrollment 32 (estimated)→35 (actual)
    + 3 other changes: verification date, contact details and site details
  2. Oct 15, 2026
    8 sites changed recruiting status (8 now active, not recruiting)
    Show 8 sites
    • Michael G Oefelein Clinical Trials ( Site 0053) · Bakersfield, United StatesRecruiting→Active, not recruiting
    • Moffitt Cancer Center ( Site 0057) · Tampa, United StatesRecruiting→Active, not recruiting
    • Northwestern University ( Site 0051) · Chicago, United StatesRecruiting→Active, not recruiting
    • Johns Hopkins University ( Site 0055) · Baltimore, United StatesRecruiting→Active, not recruiting
    • Princess Margaret Cancer Centre ( Site 0003) · Toronto, CanadaRecruiting→Active, not recruiting
    • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0002) · Sherbrooke, CanadaRecruiting→Active, not recruiting
    • Hospital Universitario Virgen de la Victoria ( Site 0043) · Málaga, SpainRecruiting→Active, not recruiting
    • Hospital Universitario 12 de Octubre ( Site 0042) · Madrid, SpainRecruiting→Active, not recruiting
    Site contacts Changed at 8 sites. See the sites
    Show 8 sites
    • Michael G Oefelein Clinical Trials ( Site 0053) · Bakersfield, United StatesContact removed •••1063
    • Moffitt Cancer Center ( Site 0057) · Tampa, United StatesContact removed •••4488
    • Northwestern University ( Site 0051) · Chicago, United StatesContact removed •••1102
    • Johns Hopkins University ( Site 0055) · Baltimore, United StatesContact removed •••0009
    • Princess Margaret Cancer Centre ( Site 0003) · Toronto, CanadaContact removed •••2246
    • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0002) · Sherbrooke, CanadaContact removed •••3446
    • Hospital Universitario Virgen de la Victoria ( Site 0043) · Málaga, SpainContact removed •••2095
    • Hospital Universitario 12 de Octubre ( Site 0042) · Madrid, SpainContact removed •••8121
  3. Oct 6, 2026
    1 site added, 1 site removed. 3 sites changed recruiting status (3 now active, not recruiting)
    Show 3 sites
    • Hôpital Claude Huriez ( Site 0012) · Lille, FranceRecruiting→Active, not recruiting
    • HENRI MONDOR HOSPITAL ( Site 0011) · Créteil, FranceRecruiting→Active, not recruiting
    • Gustave Roussy ( Site 0013) · Villejuif, FranceRecruiting→Active, not recruiting
    Show site
    • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0002) · Sherbrooke, Canada
    Show 1 removed
    • CIUSSS de l'Estrie-CHUS ( Site 0002) · Sherbrooke, Canada
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Moffitt Cancer Center ( Site 0057) · Tampa, United StatesContact •••6488→•••4488
    • Hôpital Claude Huriez ( Site 0012) · Lille, FranceContact removed •••4398
    • HENRI MONDOR HOSPITAL ( Site 0011) · Créteil, FranceContact removed •••1349
    • Gustave Roussy ( Site 0013) · Villejuif, FranceContact removed •••4211
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06637423
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Dec 20, 2024
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Nov 5, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab tirumotecan

Start the discussion